IMRX
Immuneering Corp - Ordinary Shares Class A

2,079
Loading...
Loading...
News
all
press releases
Immuneering Stock Rises 21.7% on Supply Agreement With LLY
IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.
Zacks·14d ago
News Placeholder
More News
News Placeholder
Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On Dips
Immuneering said that the company would test its lead product candidate Atebimetinib, in combination with Olomorasib, in a planned mid-stage clinical trial in patients with a type of non-small cell lung cancer who have progressed on prior therapy.
Stocktwits·14d ago
News Placeholder
Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally
The company plans to launch a pivotal trial in 2026 and expects additional clinical data and regulatory feedback by the end of 2025.
Stocktwits·3mo ago
News Placeholder
Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024
Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.
Stocktwits·9mo ago
News Placeholder
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options PR Newswire VANCOUVER, BC, Dec. 23, 2024 Issued on...
PR Newswire·9mo ago
News Placeholder
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response...
Benzinga·1y ago
News Placeholder
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment PR Newswire...
PR Newswire·1y ago
News Placeholder
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...
Globe Newswire·1y ago
News Placeholder
Immuneering price target lowered by $12 at Mizuho, here's why
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Buy Rating Affirmed for Immuneering on Solid Trial Progress and Insider Confidence
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Immuneering (IMRX Research Report) on March 27 and set a price target of...
TipRanks Financial Blog·1y ago

Latest IMRX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.